[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332677-105":59,"doc-detail-332677-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rna-modification-regulators-as-promising-biomarkers-in-gynecological-cancers","RNA modification regulators as promising biomarkers in gynecological cancers","","This review explores the evolving landscape of gynecological oncology by focusing on emerging RNA modification signatures as promising biomarkers for assessing risk and progression of ovarian, cervical, and uterine cancers. It surveys common RNA modifications with emphasis on m6A, detailing the functions of m6A “writers,” “readers,” and “erasers” in initiation and progression. It summarizes high-throughput detection methodologies and critically analyzes studies on diagnostic and prognostic biomarker potential, highlighting mechanistic insights, therapeutic targets, challenges, and future directions toward early assessment and personalized therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rna-modification-regulators-as-promising-biomarkers-in-gynecological-cancers/332677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rna-modification-regulators-as-promising-biomarkers-in-gynecological-cancers/332677.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which gynecological cancer types does the review focus on?","Question",{"text":112,"@type":113},"The review focuses on ovarian, cervical, and uterine cancers, examining how RNA modification signatures relate to risk and progression in these types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are m6A regulators, and how are they discussed in the review?",{"text":117,"@type":113},"The review highlights m6A regulators grouped as “writers,” “readers,” and “erasers,” and examines their roles in initiation and progression of gynecological cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review evaluate RNA modification biomarkers?",{"text":121,"@type":113},"It surveys methodologies for detecting RNA modifications using high-throughput, high-sensitivity techniques, then critically analyzes studies linking m6A regulators to diagnostic or prognostic biomarker potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332677,1790318470,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cell Biol Toxicol (2024) 40:92  \n[https://doi.org/10.1007/s10565-024-09924-y](https://doi.org/10.1007/s10565-024-09924-y)  \nRNA modification regulators as promising biomarkers in gynecological cancers  \nYue Qi · Tian Li · Yang Zhou · Yingying Hao ·  \nJin Zhang  \nReceived: 10 April 2024 / Accepted: 2 October 2024 / Published online: 29 October 2024 © The Author(s) 2024  \nAbstract This review explores the evolving landscape of gynecological oncology by focusing onemerging RNA modification signatures as promising biomarkers for assessing the risk and progression of ovarian, cervical, and uterine cancers. It provides a comprehensive overview of common RNA modifications, especially m6A, and their roles in cellular processes, emphasizing their implications in gynecological cancer development. The review meticulously examines specific m6A regulators including “writers”, “readers”, and “erasers” associated with three gynecological cancer types, discussing their involvement in initiation and progression. Methodologies for detecting RNA modifications are surveyed, highlighting advancements in high-throughput techniques with high sensitivity. A critical analysis of studies identifying m6A regulators as potential biomarkers is presented, addressing their diagnostic or prognostic  \nYue Qi and Yang Zhou contributed equally to this work.  \nY. Qi · Y. Zhou · Y. Hao (*) · J. Zhang (*) Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, 36 Sanhao St, Shenyang 110004, Liaoning, China  \ne-mail: [yyhao_doc@126.com](yyhao_doc@126.com)  \n[J. Zhang](J. Zhang)  \ne-mail: [2019140256@cmu.edu.cn](2019140256@cmu.edu.cn)  \nT. Li (*)  \nSchool of Basic Medicine, Fourth Military Medical University, Xi’an, Shanxi, China  \ne-mail: [fmmult@foxmail.com](fmmult@foxmail.com)  \nsignificance. Mechanistic insights into RNA modification-mediated cancer progression are explored, shedding light on molecular pathways and potential therapeutic targets. Despite current challenges, the review discusses ongoing research efforts, future directions, and the transformative possibility of RNA modifications on early assessment and personalized therapy in gynecological oncology.  \nKeywords Gynecological oncology · RNA modification · Biomarkers · m6A regulators  \nIntroduction  \nNeoplasms remain the main killer worldwide (Yang et al. 2019 ; Hu et al. 2016 ; Guo et al. 2022 ; Zhang et al. 2023 ; Cheng et al. 2012) . Among which, gynecological cancers encompass a diverse group of malignancies originating in the female reproductive system, presenting a formidable health challenge with significant morbidity and mortality worldwide (Borgeaud et al. 2023) . This heterogeneous category includes ovarian, cervical, uterine, vaginal, and vulvar cancers, each distinguished by distinct etiologies, risk factors, and clinical manifestations (Chevalier 1954 ; Van Gorp et al. 2011) . Ovarian cancer, often referred to as the \"silent killer,\" tends to manifest insidiously, leading to late-stage diagnoses and limited treatment options (Penny 2020; Webb and Jordan 2017 ; Kossaï et al. 2018) . In contrast, cervical cancer  \nis closely associated with persistent human papillomavirus (HPV) infections, making effective screening and vaccination pivotal in its prevention (Burd 2003 ; Buskwofie et al. 2020 ; Olusola et al. 2019) . Uterine cancer, primarily comprising endometrial carcinomas, underscores the intricate interplay of hormonal imbalances and genetic predispositions (Abu-Rustumet al. 2023 ; Chelmow et al. 2022 ; Whetstone et al. 2022) . Vaginal and vulvar cancers, although rarer, pose unique challenges in early detection due to their location and often nonspecific symptoms (Buchanan et al. 2016 ; Gaffney et al. 2016 ; Bray et al. 2020) .  \nThe intricacies of gynecological cancers extend beyond their anatomical origins, involving intricate molecular mechanisms that drive initiation, progression, and metastasis. RNA modifications emerge as key players in this multi","cbCaipBdI3H4NO0x","https://ap.wps.com/l/cbCaipBdI3H4NO0x","pdf",1232336,18,"English","# Abstract\n# Introduction\n## Gynecological cancer burden and heterogeneity\n## Molecular mechanisms and the role of RNA modifications\n## Need for early detection and precision risk assessment\n## Biomarkers for early detection and risk assessment\n# Review Focus (m6A and Regulators)\n## m6A writers, readers, and erasers\n## Detection methodologies for RNA modifications\n## Diagnostic and prognostic biomarker evidence\n# Mechanistic Insights and Future Directions","[{\"question\":\"Which gynecological cancer types does the review focus on?\",\"answer\":\"The review focuses on ovarian, cervical, and uterine cancers, examining how RNA modification signatures relate to risk and progression in these types.\"},{\"question\":\"What are m6A regulators, and how are they discussed in the review?\",\"answer\":\"The review highlights m6A regulators grouped as “writers,” “readers,” and “erasers,” and examines their roles in initiation and progression of gynecological cancers.\"},{\"question\":\"How does the review evaluate RNA modification biomarkers?\",\"answer\":\"It surveys methodologies for detecting RNA modifications using high-throughput, high-sensitivity techniques, then critically analyzes studies linking m6A regulators to diagnostic or prognostic biomarker potential.\"}]","RNA modification regulators as promising biomarkers in gynecological cancers | PDF",1789999042,45]